Table 3.
Relationship between clinicopathological characteristics and risk score calculated by using the 9-lncRNAs signature
| Factor | Risk scorea | P value | |
|---|---|---|---|
| Low | High | ||
| Gender | |||
| Male | 175 (67.83%) | 163 (63.18%) | 0.266 |
| Female | 83 (32.17%) | 95 (36.82%) | |
| Age | |||
| > 60 | 120 (46.51%) | 137 (53.10%) | 0.135 |
| ≤ 60 | 138 (53.49%) | 121 (46.90%) | |
| Grade | |||
| G1 + 2 | 139 (54.51%) | 93 (36.76%) | < 0.001 |
| G3 + 4 | 116 (45.49%) | 160 (63.24%) | |
| N stage | |||
| N0 | 111 (98.23%) | 123 (89.78%) | 0.008 |
| N1 | 2 (1.77%) | 14 (10.22%) | |
| T stage | |||
| T1 + 2 | 193 (98.23%) | 136 (89.78%) | 0.007 |
| T3 + 4 | 65 (1.77%) | 122 (10.22%) | |
| M stage | |||
| M0 | 233 (90.66%) | 193 (77.51%) | < 0.001 |
| M1 | 24 (9.34%) | 56 (22.49%) | |
| TNM stage | |||
| I + II | 185 (71.98%) | 126 (49.22%) | < 0.001 |
| III + IV | 72 (28.02%) | 130 (50.78%) | |
| Status | |||
| Live | 214 (82.95%) | 133 (51.55%) | < 0.001 |
| Dead | 44 (17.05%) | 125 (48.45%) | |
aMedian expression of risk score was used as cut-off value to cut the patients into high risk group and low risk group